Masucci et al., 2010 - Google Patents
Survival of the fittest or best adapted: HLA-dependent tumor developmentMasucci et al., 2010
View PDF- Document ID
- 456179432632990330
- Author
- Masucci G
- Andersson E
- Villabona L
- Helgadottir H
- Bergfeldt K
- Cavallo F
- Forni G
- Ferrone S
- Choudhury A
- Seliger B
- Kiessling R
- Publication year
- Publication venue
- Journal of Nucleic Acids Investigation
External Links
Snippet
Abstract The major histocompatibility complex (MHC) comprises a set of genes that are critical to immunity and surveillance against neoplastic transformation. There is increasing evidence that the MHC antigens not only regulate antitumor immune responses in …
- 230000004083 survival 0 title abstract description 17
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220288180A1 (en) | Antigen-specific t cell receptors and t cell epitopes | |
| Kawano et al. | Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression | |
| CN107735492B (en) | Methods of treating cancer using activated T cells | |
| Cappello et al. | Alpha-Enolase (ENO1), a potential target in novel immunotherapies | |
| Lu et al. | A novel multi‐epitope vaccine from MMSA‐1 and DKK 1 for multiple myeloma immunotherapy | |
| Zilberberg et al. | Strategies for the identification of T cell–recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation | |
| TW201742923A (en) | Sequence arrangements and sequences for neoepitope presentation | |
| Boß et al. | Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen | |
| Tomita et al. | Peptides derived from human insulin‐like growth factor‐II mRNA binding protein 3 can induce human leukocyte antigen‐A2‐restricted cytotoxic T lymphocytes reactive to cancer cells | |
| Zahavi et al. | Tumor mechanisms of resistance to immune attack | |
| Sun et al. | Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer | |
| Masucci et al. | Survival of the fittest or best adapted: HLA-dependent tumor development | |
| CN117731781A (en) | Application of NAT10 promoter in preparation of synergist for enhancing liver cancer immunotherapy effect | |
| Masucci et al. | Kjell Bergfeldt, Federica Cavallo, 2 Guido Forni, 2 Soldano Ferrone, 3 Aniruddha Choudhury, Barbara Seliger, 4 Rolf Kiessling Dept. Oncology-Pathology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden; 2 Molecular Biotechnology Center, Dept of Clinical and Biological Sciences, University of Torino, Torino, Italy; 3 University of Pittsburgh Cancer Institute, Departments of Surgery, Immunology and Pathology, School of Medicine, Pittsburgh, PA, USA; 4 Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany | |
| Wu et al. | Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond | |
| Smith et al. | Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination | |
| Gandolfi | Landscape of molecular events regulating multiple myeloma cell responses to natural killer cells | |
| WO2024101994A1 (en) | T cell receptors directed against cancer-associated antigens and uses thereof | |
| Forni et al. | Survival of the fittest or best adapted–H | |
| Frøsig | Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma | |
| Immunother | International Society for Biological Therapy of Cancer | |
| Schröder | Tumor-specific CD8 T cells in a primary human breast carcinoma: a detailed analysis | |
| Clay et al. | Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy |